SLC5A2 and chronic kidney disease: Recent advancements, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have shown significant benefits in improving both cardiovascular and renal outcomes.[30] These therapies represent a shift in diabetes management, particularly for CKD patients.